ArticleScientific reports2025
Selenium protected NMRI mice against methotrexate induced testicular injury : Selenium effectiveness in methotrexate treated testis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methotrexate (MTX) is used to treat malignant and autoimmune disorders, while it also hurts testicular tissue leading to infertility. It has been shown that MTX induces testicular injury by producing oxidative stress, inflammatory cytokines, and apoptotic cascades, but its molecular mechanisms have not been fully investigated. Selenium (Se) with antioxidant properties is protective in testicular germ cells. The use of Se to modulate the oxidative stress caused by MTX was investigated in this study, focusing on P38 and NF-κB pathways in the testis of NMRI mice treated models with MTX. The control, MTX, Se, and MTX + Se groups were considered the male mice in this study. RNA extraction was utilized to examine the P38 and NF-κB gene expression by Real-time quantitative polymerase chain reaction (RT-qPCR). The testicular protein samples were extracted to analyze the protein expression of P38 and NF-κB. The assessment of TNF-α, IL-1β, and IL-6 levels was examined using ELISA. Tukey's tests and ANOVA were used for statistical analysis (p < 0.05). The increased significantly of P38 and NF-κB mRNA expression and up-regulation of P38 and NF-κB proteins were observed in the group treated with MTX compared to the control group while the administration of Se caused a significant decrease in the mRNA or proteins expression. The TNF-α, IL-6 and IL-1β protein expression in the following MTX treatment, in testis tissue, was raised significantly, and co-treatment with Se significantly reduced the testis tissue level of TNF-α, IL-6 and IL-1β protein in contrast to that of the MTX group. Our findings show the potential of Se as a medicine to modulate the destructive effects of MTX in testicular tissue which suggests Se supplementation as a viable method to prevent testicular damage from chemotherapy and maintain male fertility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.